Horizon Capital Invests in Viseven, Leading Global Pharma and Life Sciences MarTech Provider
Posted:
Horizon Capital, a U.S. private equity firm investing primarily in fast-growing tech and export-oriented businesses in Ukraine, announced an investment in Viseven, a leading global marketing tech provider servicing the pharma and life sciences industry. This transaction marks the third investment from its latest fund, Horizon Capital Growth Fund IV (HCGF IV), which reached $328 million at its most recent closing held in December 2023.
Antimicrobial resistance could claim almost two million lives a year by 2050. Now, researchers believe they could use #AI to predict which bugs will become resistant so that we can better prepare.
Read the full article here.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient…
Attendees
Sponsors and Exhibitors
AI In Healthcare: A Virtual Course
Contact us